BioCryst Pharma (BCRX) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St falls as oil ticks up, yields rise ahead of US-China summit
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil holds near two-week lows while diesel cracks hit record
BioCryst Reports Second Quarter 2022 Financial Results and Upcoming Key Milestones
August 4, 2022 7:00 AM EDTQ2 2022 ORLADEYO net revenue of $65.2 million
FY 2022 ORLADEYO net revenue expected to be between $255 million and $265 million
RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today reported financial results for the second quarter ended June 30, 2022, and provided a corporate update.
... More